Evidence map›Paper›PMID 32939867›Full record

Observational studyCancer science2020

No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.

Eo Toriyama, Tomoko Hata, Ken-Ichi Yokota, Masahiko Chiwata, Rena Kamijo, Miki Hashimoto, Masataka Taguchi, Makiko Horai, Masatoshi Matsuo, Emi Matsuo and 13 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Eo ToriyamaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tomoko HataDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-9115-1749
Ken-Ichi YokotaBiostatistics Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Masahiko ChiwataDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Rena KamijoDepartment of Hematology, Sasebo City General Medical Center, Sasebo, Japan.
Miki HashimotoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masataka TaguchiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-0642-5814
Makiko HoraiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Masatoshi MatsuoDepartment of Hematology, Nagasaki Harbor Medical Center, Nagasaki, Japan.
Emi MatsuoDepartment of Hematology, Japan Community Health Care Organization Isahaya General Hospital, Isahaya, Japan.
Yumi TakasakiDepartment of Internal Medicine, Saint Francis Hospital, Nagasaki, Japan.
Yasuhisa KawaguchiDepartment of Internal Medicine, National Hospital Organization Nagasaki Hospital, Nagasaki, Japan.
Hidehiro ItonagaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Koji AndoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Yasushi SawayamaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Jun TaguchiDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-2954-5691
Hideki TsushimaDepartment of Hematology, Nagasaki Harbor Medical Center, Nagasaki, Japan.
Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Shinichiro YoshidaDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Medical Center, Sasebo, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University · JPNagasaki University Hospital · JPNagasaki Medical Center · JPJapanese Red Cross Society, Japan · JPSasebo City General Hospital · JPJapan Community Healthcare Organization · JP

Funding

MEXT KAKENHI 17H04209MEXT KAKENHI 20H03712Ministry of Health -026Ministry of Health H29-Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical ScienceResearch Program of Intractable Disease provided by Ministry of Health, Labor, and Welfare (MHLW) of Japan H29-Nanchi-Ippan-026
6 · The paper itself

Abstract

The efficacy of azacitidine (AZA) on survival of lower risk (LR) - myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long-term survival benefit of AZA for patients with LR-MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR-MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis-stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection-related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR-MDS patients.

Indexed as

AdultAgedAged, 80 and overAge FactorsAntimetabolites, AntineoplasticAzacitidineCause of DeathErythrocyte TransfusionFemaleHematinicsHumansImmunosuppressive AgentsInduction ChemotherapyJapanKaplan-Meier EstimateMaleAntimetabolites, AntineoplasticAzacitidineHematinicsImmunosuppressive Agentscharacteristics and pathology of human cancerchemotherapy and endocrine therapyepigenetic therapyhematopoietic organ

Identifiers

PMID32939867
PMCPMC7734160
OpenAlexW3087355768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.